Companies such as Allogene Therapeutics and Celyad Oncology have developed allogeneic CAR-T cells that target BCMA, demonstrating potential in preclinical and early clinical studies.444,445 Pan et al. recently reported the results of a phase 1 trial of allogeneic CD5-specific CAR-T therapy for the treatment of relapsed/refractory T-ALL. The gene discussed is CD5; the disease is acute lymphoblastic leukemia.